KR20110044883A - 신규한 조성물 및 방법 - Google Patents

신규한 조성물 및 방법 Download PDF

Info

Publication number
KR20110044883A
KR20110044883A KR1020117004640A KR20117004640A KR20110044883A KR 20110044883 A KR20110044883 A KR 20110044883A KR 1020117004640 A KR1020117004640 A KR 1020117004640A KR 20117004640 A KR20117004640 A KR 20117004640A KR 20110044883 A KR20110044883 A KR 20110044883A
Authority
KR
South Korea
Prior art keywords
polypeptide
protein sequence
rv3616c protein
tuberculosis
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117004640A
Other languages
English (en)
Korean (ko)
Inventor
제임스 브라운
파스칼 메텐스
데니스 머피
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이., 글락소 그룹 리미티드 filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20110044883A publication Critical patent/KR20110044883A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020117004640A 2008-07-25 2009-07-24 신규한 조성물 및 방법 Ceased KR20110044883A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
US61/083,720 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
KR20110044883A true KR20110044883A (ko) 2011-05-02

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004640A Ceased KR20110044883A (ko) 2008-07-25 2009-07-24 신규한 조성물 및 방법

Country Status (24)

Country Link
US (2) US20110117119A1 (cg-RX-API-DMAC7.html)
EP (1) EP2315773B1 (cg-RX-API-DMAC7.html)
JP (1) JP5873332B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110044883A (cg-RX-API-DMAC7.html)
CN (1) CN102164952B (cg-RX-API-DMAC7.html)
AU (1) AU2009273130B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2731499C (cg-RX-API-DMAC7.html)
CO (1) CO6341637A2 (cg-RX-API-DMAC7.html)
CY (1) CY1118200T1 (cg-RX-API-DMAC7.html)
DK (1) DK2315773T3 (cg-RX-API-DMAC7.html)
EA (1) EA024826B1 (cg-RX-API-DMAC7.html)
ES (1) ES2602430T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161458T1 (cg-RX-API-DMAC7.html)
HU (1) HUE031044T2 (cg-RX-API-DMAC7.html)
IL (1) IL210559A0 (cg-RX-API-DMAC7.html)
LT (1) LT2315773T (cg-RX-API-DMAC7.html)
MX (1) MX2011000983A (cg-RX-API-DMAC7.html)
PL (1) PL2315773T3 (cg-RX-API-DMAC7.html)
PT (1) PT2315773T (cg-RX-API-DMAC7.html)
SG (1) SG192456A1 (cg-RX-API-DMAC7.html)
SI (1) SI2315773T1 (cg-RX-API-DMAC7.html)
UA (1) UA107330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010010177A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940406B2 (en) 2008-08-13 2015-01-27 Novelis Inc. Automobile body part

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026248A2 (en) * 1998-11-04 2000-05-11 Isis Innovation Limited Tuberculosis diagnostic test
LT2315834T (lt) 2008-07-25 2018-09-10 Glaxosmithkline Biologicals S.A. Tuberkuliozės rv2386c baltymas, kompozicijos ir jų panaudojimas
ES2647321T3 (es) 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
JP6857029B2 (ja) 2013-09-27 2021-04-14 コデクシス， インコーポレイテッド 酵素バリアントの自動スクリーニング
HUE048104T2 (hu) * 2013-09-27 2020-05-28 Codexis Inc Szerkezet alapú prediktív modellezés
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CA3252762A1 (en) 2019-04-12 2025-07-08 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
DK2133100T3 (da) * 2000-06-20 2012-01-23 Corixa Corp MTB32A-Antigen af Mycobacterium tuberculosis med inaktiveret aktivt sted og fusionsproteiner deraf
CZ20031866A3 (cs) * 2001-01-08 2004-03-17 Isis Innovation Limited Způsob pro stanovení účinnosti léčení mykobakteriální infekce
CN1277843C (zh) * 2001-02-22 2006-10-04 巴斯德研究院 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP1781313A4 (en) * 2004-06-17 2009-08-26 Beckman Coulter Inc MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
EP2457926B1 (en) 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
EP2380589A3 (en) * 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
HRP20161608T1 (hr) 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940406B2 (en) 2008-08-13 2015-01-27 Novelis Inc. Automobile body part

Also Published As

Publication number Publication date
IL210559A0 (en) 2011-03-31
AU2009273130B2 (en) 2014-10-16
HUE031044T2 (en) 2017-06-28
CN102164952A (zh) 2011-08-24
PL2315773T3 (pl) 2017-07-31
ES2602430T3 (es) 2017-02-21
CO6341637A2 (es) 2011-11-21
AU2009273130A1 (en) 2010-01-28
UA107330C2 (uk) 2014-12-25
SG192456A1 (en) 2013-08-30
EP2315773B1 (en) 2016-08-24
EA201100072A1 (ru) 2011-10-31
DK2315773T3 (en) 2016-12-12
CA2731499A1 (en) 2010-01-28
HRP20161458T1 (hr) 2016-12-16
CY1118200T1 (el) 2017-06-28
JP2011528895A (ja) 2011-12-01
US20110117119A1 (en) 2011-05-19
CN102164952B (zh) 2016-05-25
EA024826B1 (ru) 2016-10-31
LT2315773T (lt) 2016-11-10
BRPI0916703A2 (pt) 2019-12-24
PT2315773T (pt) 2016-11-23
MX2011000983A (es) 2011-03-02
EP2315773A1 (en) 2011-05-04
SI2315773T1 (sl) 2016-12-30
US20140178423A1 (en) 2014-06-26
WO2010010177A1 (en) 2010-01-28
JP5873332B2 (ja) 2016-03-01
US9795663B2 (en) 2017-10-24
CA2731499C (en) 2017-01-10

Similar Documents

Publication Publication Date Title
JP6104326B2 (ja) 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP5873332B2 (ja) 新規化合物および方法
JP5824360B2 (ja) 新規化合物および方法
WO2010010178A1 (en) The tuberculosis rv2707c protein, compositions and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151126

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160527

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I